<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593123</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14-10739</org_study_id>
    <secondary_id>HM20005586</secondary_id>
    <nct_id>NCT02593123</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis</brief_title>
  <official_title>Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massey Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients
      receiving the investigational regimen.This is a randomized phase II clinical trial, comparing
      two different dosing schedules of mycophyenolate mofetil for graft versus host disease (GVHD)
      prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and
      non-relapse mortality will be assessed. Adaptive randomization between two study arms will be
      performed based on T cell counts at day 60.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will utilize a regimen combining low dose total body
      irradiation and rabbit ATG to facilitate stem cell transplantation (SCT) with HLA matched
      related and unrelated donors. Based on the hypothesis that early treatment interventions have
      significant late effects in allogeneic SCT, a simple intervention, varying the duration of
      intense immunosuppression following SCT, will be investigated in this study. This may allow
      more robust recovery of donor immune system cells in the first two months following
      transplantation and eventually result in lower risk of cancer relapse, while maintaining
      effective graft versus host disease (GVHD) control. Patients will be randomly assigned to
      receive GVHD prevention therapy using one of two different immunosuppressive regimens with
      tacrolimus &amp; mycophenolate mofetil (MMF). Patients assigned to the investigational group will
      receive MMF for 15 days following SCT with growth factor support using granulocyte macrophage
      colony stimulating factor (GM-CSF) beginning on post-transplant day 4. Patients randomized to
      the standard treatment group will receive MMF for 30 days following SCT with cytokine support
      using granulocyte colony stimulating factor (G-CSF) beginning on post-transplant day 4. If
      one of these treatment groups demonstrates an improvement in donor immune cell recovery,
      there may be a slow increase in the likelihood of patients being assigned to that more
      successful treatment group. Eventually the two groups will be compared with respect to the
      likelihood of either relapse or GVHD developing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 4, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The differences in the relapse-free/donor lymphocyte infusion(DLI)-free survival rates between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome in this study is event-free survival, where the conditional events are the occurrence of relapse or DLI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) day 60 donor-derived (dd) cluster of differentiation (CD)3.</measure>
    <time_frame>5 years</time_frame>
    <description>Day 60 donor-derived (dd) cluster of differentiation (CD)3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the Overall survival (OS) between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival (days to event or survival: time-to-event; survival: categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of acute GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Acute GVHD (days to positive diagnosis: time-to-event; positive diagnosis: categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of chronic GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Chronic GVHD (days to positive diagnosis: time-to-event; positive diagnosis: categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of opportunistic infections between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of opportunistic infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of graft loss between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Engraftment loss (days to loss: time-to-event; graft loss: categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of engraftment syndrome between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)</measure>
    <time_frame>5 years</time_frame>
    <description>Engraftment syndrome (categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of achieving donor chimerisms between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).</measure>
    <time_frame>5 years</time_frame>
    <description>DLI administration (days to administration: time-to-event; administration: categorical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences in the rates of T-cell recovery kinetics following SCT between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).</measure>
    <time_frame>5 years</time_frame>
    <description>Rates of T-cell recovery following SCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Lymphoid Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Myeloma</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Recurrent Acute Myeloid Leukemia, Adult</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Recurrent Chronic Lymphocytic Leukemia</condition>
  <condition>Recurrent Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I (MMF-15, sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive mycophenolate mofetil PO or IV BID on days 1-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (MMF-30, filgrastim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive mycophenolate mofetil PO or IV BID on days 1-30 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO, by mouth, orally or IV, intravenous medication administration.</description>
    <arm_group_label>Arm I (MMF-15, sargramostim)</arm_group_label>
    <arm_group_label>Arm II (MMF-30, filgrastim)</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.
Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF.</description>
    <arm_group_label>Arm I (MMF-15, sargramostim)</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>colony stimulating factor 2</other_name>
    <other_name>CSF2</other_name>
    <other_name>granulocyte macrophage colony stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.</description>
    <arm_group_label>Arm II (MMF-30, filgrastim)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>GCSF</other_name>
    <other_name>colony-stimulating factor 3</other_name>
    <other_name>CSF 3</other_name>
    <other_name>granulocyte colony stimulating factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Any of the following high risk or recurrent hematological malignancies:

          -  Hodgkin lymphoma (HL)

          -  Non-Hodgkin lymphoma (NHL)

          -  Chronic lymphocytic leukemia (CLL)

          -  Multiple myeloma (MM)

          -  Acute myelogenous leukemia (AML)

          -  Acute lymphocytic leukemia (ALL)

          -  Chronic myelogenous leukemia (CML)

          -  Myelodysplastic syndrome (MDS)

             *Note: Determination that the malignancy is high risk will be made by the
             investigator.

          -  Investigator determination that the patient is an appropriate candidate for reduced
             intensity allogeneic SCT with the standard Massey Cancer Center-Virginia Commonwealth
             Health System Bone Marrow Transplant MCC-VCUHS BMT Program regimen employed in this
             trial

          -  Patients with or without previous myeloablative autologous transplant

          -  HLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated
             (8/8 or 7/8 loci matched)

             *Note: Unrelated donors must be matched at HLA-A, -B, -C, and -DRB1 loci. However, a
             single locus mismatch will be acceptable in the event a more closely matched donor is
             not available.

          -  Age â‰¥ 40 to &lt; 75 years; patients 18 to 39 years of age will be eligible only if the
             investigator has determined that the patient has comorbidity(ies) precluding
             conventional allogeneic transplantation with full intensity myeloablative conditioning

          -  Karnofsky Performance Status of 70-100%

          -  Negative serology for HIV

          -  Women who are not postmenopausal or have not undergone hysterectomy must have a
             documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines

          -  Ability to understand and the willingness to sign a written informed consent document
             *Note: The consent form must be signed and dated prior to initiation of SCT
             preparative treatments.

        Exclusion Criteria

          -  Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance
             doses as determined by a radiation oncologist

          -  Uncontrolled viral, fungal, or bacterial infection

          -  Active meningeal or central nervous system disease

          -  Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with
             equine ATG is allowed if more than 3 months ago

             *Note: Previous myeloablative autologous transplant is permitted but not required.

          -  Pregnancy or breastfeeding

          -  Medical, psychological, or social condition that, in the opinion of the investigator,
             may increase the patient's risk or limit the patient's adherence with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir A Toor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine H Roberts, Ph.D.</last_name>
    <phone>804-828-1292</phone>
    <email>croberts2@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir A Toor, MD</last_name>
    <phone>804-628-2389</phone>
    <email>amir.toor@vcuhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Roberts, PhD</last_name>
      <phone>804-828-1292</phone>
      <email>croberts2@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amir A Toor, MD</last_name>
      <phone>804-628-2389</phone>
      <email>amir.toor@vcuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amir A Toor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donor Type (Matched Related Donor or Matched Unrelated Donor)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

